Galectin Therapeutics Inc. (OTC: GALT) (“the Company”), the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin receptors, today announced the formation of its Liver Fibrosis Clinical Trials Advisory Board comprised of key opinion leaders from Emory Hospital and School of Medicine, Massachusetts General Hospital and Harvard School of Medicine, University of Michigan Hospital and School of Medicine, Mount Sinai Hospital and School of Medicine, and University of Wisconsin Hospital and School of Medicine. The Company expects to file an Investigational New Drug application to treat liver fibrosis with the U.S. Food and Drug Administration and plans to initiate a clinical trial next year.
“Galectin Therapeutics has assembled an outstanding group of investigators and clinicians to help guide our clinical strategy and clinical trial design in liver fibrosis and additionally serve as principle investigators on clinical trials,” said Dr. Peter Traber, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics, Inc. “Our most advanced programs, the GM and GR series of compounds, have demonstrated the ability to arrest and reverse liver fibrosis in pre-clinical studies. There are currently no treatment options for liver fibrosis except liver transplantation. Our goal is to develop the first therapy for liver fibrosis and we expect to advance a lead candidate into clinical trials in 2012.”
Principal Investigators named to the Liver Fibrosis Clinical Trials Advisory Board include:
- Dr. Ram Subramanian, Emory Hospital and School of Medicine: Dr. Subramanian is Assistant Professor of Medicine and specializes in gastroenterology, transplant hepatology, pulmonary medicine and critical care. Areas of interest include acute liver failure, decompensated cirrhosis, hepatic critical care and pre and post liver transplant care.
- Dr. Raymond T. Chung, Massachusetts General Hospital and Harvard School of Medicine: Dr. Chung is Professor of Medicine and Vice Chief of Gastroenterology, Director of Hepatology, and Medical Director, Liver Transplant Program. His interests are viral hepatitis, liver cancer, and liver transplantation.
- Dr. Robert J. Fontana, University of Michigan and School of Medicine: Dr. Fontana is Professor of Medicine and the Medical Director, Liver Transplant Program. His clinical and research interests include drug-induced liver disease, viral hepatitis, and acute liver failure.
- Dr. Thomas D. Schiano, Mount Sinai Hospital and School of Medicine: Dr. Schiano is Professor of Medicine with specialty in liver disease and has a clinical background in hepatology, gastroenterology and clinical nutrition. He has expertise in the management of persons with cirrhosis and other acute/chronic liver diseases, and in caring for patients prior to and after liver transplantation.
- Dr. Michael R. Lucey, University of Wisconsin Hospital and School of Medicine: Dr. Lucey is Professor of Medicine and Chief, Gastroenterology and Hepatology. His clinical interests are hepatology and liver transplant medicine. His research interests include alcoholic liver disease, viral hepatitis, and care of patients before and after liver transplantation.
Principal Consultants for the Liver Fibrosis Clinical Trials Advisory Board include:
- Dr. Scott L. Friedman, Mount Sinai Hospital and School of Medicine: Dr. Friedman is Professor of Medicine and Director of the Section of Liver Disease. Dr. Friedman has performed pioneering research into the underlying causes of scarring, or fibrosis, associated with chronic liver disease, which affects millions worldwide. He was the first to isolate and characterize the hepatic stellate cell, which is the key cell type responsible for scar production in liver.
- Dr. Maria Isabel Fiel, Mount Sinai Hospital and School of Medicine: Dr. Fiel is a Professor of Pathology. Dr. Fiel’s specialties include Anatomic pathology, Cytopathology and Clinical pathology. Having finished two fellowships in Liver & Transplant Pathology and Cytopathology, her main clinical interests include Liver Pathology and Gastrointestinal Pathology, and she has published extensively in the areas of viral hepatitis, alcoholic liver disease, non-cirrhotic portal hypertension, liver cancer and liver fibrosis. In addition, Dr. Fiel is Director of the Mount Sinai Alcohol Liver Disease Research Center.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV